Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 118 articles: HTML format

Single Articles

August 2026
1. HAO WP, Lin ZB, Ke L, Liu HJ, et al
   Overexpression of small nucleolar RNA host gene family members predicts poor bladder cancer prognosis: based on a systematic review and meta-analysis.
   BMC Cancer. 2026;26:1324.
   PubMed     Abstract available
   
   
   July 2026
2. SAKAI R, Shimada H, Hata S, Yokoyama A, et al
   Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells.
   BMC Cancer. 2026;26:1283.
   PubMed     Abstract available
   
   
   
3. KURAL S, Kumar L, Pathak AK, Singh S, et al
   Non-invasive diagnostic evaluation of urinary exosomal let-7c cluster expression in bladder cancer using machine learning approaches.
   BMC Cancer. 2026 Jul 21. doi: 10.1186/s12885-026-16217.
   PubMed     Abstract available
   
   
   
4. MOHANTY P, Subhangini M
   Immunohistochemical evaluation of molecular subtypes in muscle invasive bladder cancer with demographic correlation.
   BMC Cancer. 2026 Jul 10. doi: 10.1186/s12885-026-16476.
   PubMed     Abstract available
   
   
   June 2026
5. HAO X, Ye C, Lai W, Xu J, et al
   Urologic malignancy in renal transplant recipients: Analysis of OPTN/UNOS data from 2000 to 2022.
   BMC Cancer. 2026;26:805.
   PubMed     Abstract available
   
   
   
6. YI L, Ma Z, Zhang J, Zhan Y, et al
   A stratified urine-based molecular diagnostic and prognostic model for non-muscle-invasive bladder cancer management.
   BMC Cancer. 2026 Jun 22. doi: 10.1186/s12885-026-16361.
   PubMed     Abstract available
   
   
   
7. ALTIN E, Dogan C, Arslan AI, Topkac EC, et al
   ELF-3 and TSC-1 as potential markers of recurrence in low-risk non-muscle-invasive bladder cancer.
   BMC Cancer. 2026 Jun 20. doi: 10.1186/s12885-026-16314.
   PubMed     Abstract available
   
   
   
8. HU P, Wang C, Zeng X, Jin S, et al
   The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of bladder cancer patients: a systematic review and meta-analysis.
   BMC Cancer. 2026 Jun 13. doi: 10.1186/s12885-026-16326.
   PubMed     Abstract available
   
   
   
9. WANG T, Jiang X
   Toripalimab plus disitamab vedotin versus tislelizumab-based combination in advanced urothelial carcinoma: a real-world comparative study.
   BMC Cancer. 2026;26:997.
   PubMed     Abstract available
   
   
   
10. TAMBARO R, Calvanese G, Muto A, Formisano L, et al
    Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).
    BMC Cancer. 2026;26:956.
    PubMed     Abstract available
    
    
    May 2026
11. CHEN C, Liu X, Xu A, Jiang N, et al
    Transcriptomic analysis of genes in bladder cancer patients with resistance to neoadjuvant chemoimmunotherapy.
    BMC Cancer. 2026 May 26. doi: 10.1186/s12885-026-16165.
    PubMed     Abstract available
    
    
    
12. WANG Y, Ailiyaer A, Chen S, Wang W, et al
    Development and internal validation of an explainable machine-learning model to predict 3-year overall survival rate after radical cystectomy.
    BMC Cancer. 2026;26:813.
    PubMed     Abstract available
    
    
    April 2026
13. RIZZO A, Ciccimarra F, de Casio Zequi S, Bove S, et al
    Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2(EV) project.
    BMC Cancer. 2026;26:756.
    PubMed     Abstract available
    
    
    
14. WU Q, Lu P, Zhang X, Qing X, et al
    Persistent follicular cystitis following intravesical gemcitabine: a case series and literature review.
    BMC Cancer. 2026;26:680.
    PubMed     Abstract available
    
    
    
15. TANUMA K, Shiga M, Sano K, Hamada K, et al
    Systemic administration of liposomal trehalose dimycolate induces NK1.1(+) cell mediated antitumor immunity in bladder cancer.
    BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15951.
    PubMed    
    
    
    March 2026
16. KIM JH, Maeng S, Choi J, Lee CU, et al
    The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-guerin and an anti-PD-1 inhibitor in bladder cancer.
    BMC Cancer. 2026 Mar 29. doi: 10.1186/s12885-026-15890.
    PubMed    
    
    
    
17. HUO X, Qi J, Zhu Y, Song H, et al
    Integrative analysis of adenosine-related RNA modifications defines molecular subtypes of bladder cancer and identifies CES1 as a driver of tumor progression and immunotherapy resistance.
    BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15897.
    PubMed    
    
    
    
18. FEKNER Z, Sieracka J, Dabrowski P, Kazmierski L, et al
    Mumio and bladder cancer: unlocking its potential in 3D cell culture.
    BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15838.
    PubMed    
    
    
    February 2026
19. ZHANG L, Cao J, Gao Z, Han C, et al
    Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer.
    BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15806.
    PubMed    
    
    
    
20. GAO WB, Yu JJ
    Celldetect test performance in monitoring bladder cancer recurrence after transurethral resection.
    BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15797.
    PubMed    
    
    
    
21. ZEBER-LUBECKA N, Bilski K, Dabrowska M, Goryca K, et al
    Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing.
    BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15666.
    PubMed     Abstract available
    
    
    
22. ISKENDER B, Sarihan M, Barlak BSR, Akpinar G, et al
    Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation.
    BMC Cancer. 2026 Feb 6. doi: 10.1186/s12885-026-15634.
    PubMed    
    
    
    
23. OSAKA K, Kishida T, Umemoto S, Karashima T, et al
    Evaluation of variations in urine laminin-gamma2 monomer in non-muscle-invasive bladder cancer before and after transurethral resection of the bladder tumor.
    BMC Cancer. 2026 Feb 2. doi: 10.1186/s12885-026-15658.
    PubMed    
    
    
    January 2026
24. RAO XP, Zou XC, Yu ZJ, Yuan YY, et al
    Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.
    BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-026-15554.
    PubMed     Abstract available
    
    
    December 2025
25. BLONDEAU A, Pitout A, Manuguerra A, Eschwege P, et al
    Sarcopenia measured by artificial intelligence as a predictor of overall survival in localized bladder cancer, a multicenter study.
    BMC Cancer. 2025 Dec 11. doi: 10.1186/s12885-025-15363.
    PubMed     Abstract available
    
    
    
26. LAN K, Zhang Y, Luo Y, Hong T, et al
    Global, regional, and national burdens of bladder cancer attributable to high fasting plasma glucose from 1990 to 2021, with future forecasts to 2050: a systematic analysis for the global burden of disease study 2021.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15359.
    PubMed     Abstract available
    
    
    
27. DU C, Wei W, Hu M, He J, et al
    Enhancing prediction accuracy for muscle invasion in bladder cancer using a dual-energy CT-based interpretable model incorporating habitat radiomics and deep learning.
    BMC Cancer. 2025;25:1842.
    PubMed     Abstract available
    
    
    November 2025
28. YANG IN, Liang CA, Wu CC, Xu QS, et al
    Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non-muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients.
    BMC Cancer. 2025;25:1900.
    PubMed     Abstract available
    
    
    
29. ZHAO Y, Li P, Shen Z, Yao S, et al
    Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence.
    BMC Cancer. 2025;25:1796.
    PubMed     Abstract available
    
    
    
30. LEE SY, Lee YH, Kim TM, Ha US, et al
    TGF-beta signaling and tumor microenvironment dynamics in bladder cancer progression post-BCG therapy: a longitudinal single-nucleus RNA-seq study.
    BMC Cancer. 2025;25:1735.
    PubMed     Abstract available
    
    
    
31. HU D, Liu H, Li M, Wu W, et al
    Prognostic value of prostate volume and nomograms for predicting recurrence in patients with non-muscle invasive bladder cancer: a multi-institutional study.
    BMC Cancer. 2025;25:1719.
    PubMed     Abstract available
    
    
    
32. ZHAO Y, Ji Z, Sun W, Liu X, et al
    Plasma lipidomics for biomarker identification in non-muscle invasive bladder cancer.
    BMC Cancer. 2025;25:1702.
    PubMed     Abstract available
    
    
    October 2025
33. ZHENG J, Lu S, Zhang Q, Zhang L, et al
    Development and external validation of a FISH-clinical nomogram for predicting overall survival in bladder cancer patients after radical cystectomy.
    BMC Cancer. 2025;25:1648.
    PubMed     Abstract available
    
    
    
34. FANG C, Huang X, Dai J, He W, et al
    Retraction Note: The circular RNA circfarsa sponges microRNA-330-5p in tumor cells with bladder cancer phenotype.
    BMC Cancer. 2025;25:1613.
    PubMed    
    
    
    
35. LI W, Shi Y, Pu L, Zhang J, et al
    Shared decision-making in urinary reconstruction among radical cystectomy patients: a thematic analysis of patient and provider perspectives in China.
    BMC Cancer. 2025;25:1590.
    PubMed     Abstract available
    
    
    
36. YEH CC, Tsai PC, Song YD, Low YS, et al
    Metformin as an anti-cancer agent against bladder cancer acts via PD-L1 downregulation in an orthotopic mouse model.
    BMC Cancer. 2025;25:1534.
    PubMed     Abstract available
    
    
    
37. KANAAN MR, Schmitz J, Braesen JH, Kuczyk MA, et al
    Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs.
    BMC Cancer. 2025;25:1525.
    PubMed     Abstract available
    
    
    
38. ABOULHODA BE, Omar AM, Elfarrash S, Alghamdi MA, et al
    Novel anticancer effect of substituted imidazole derivatives against urothelial carcinoma: integrating In vitro screening and molecular docking for target kinases.
    BMC Cancer. 2025;25:1524.
    PubMed     Abstract available
    
    
    
39. CHEN B, Zhou Y, Li Z, Chen J, et al
    A study on predicting recurrence of non-muscle-invasive bladder cancer within 2 years using mp-MRI radiomics.
    BMC Cancer. 2025;25:1497.
    PubMed    
    
    
    September 2025
40. LIU S, Lei K, Li G, Zheng P, et al
    The integration of transcriptomics and metabolomics elucidates the antitumor mechanisms of mycophenolic acid in bladder cancer cells.
    BMC Cancer. 2025;25:1463.
    PubMed     Abstract available
    
    
    
41. ZHANG J, Cheng X, Huang C, Xu Y, et al
    The diagnostic performance of a noninvasive urine-based methylation biomarkers Vimentin/POU4F2 to detect bladder carcinoma.
    BMC Cancer. 2025;25:1460.
    PubMed     Abstract available
    
    
    
42. LI C, Liu J, Wang L, Xiong W, et al
    Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer immunotherapy by inhibiting CD276 expression.
    BMC Cancer. 2025;25:1404.
    PubMed     Abstract available
    
    
    July 2025
43. RAHATIJAFARABAD B, Poorkhani A, Esfandiari F, Sedaghat S, et al
    Trends in urinary tract cancer incidence in Golestan province, Iran: a 16-year population-based study.
    BMC Cancer. 2025;25:1227.
    PubMed     Abstract available
    
    
    
44. LI J, Liang J, Xu Y, Tan W, et al
    Droplet digital PCR assay for precise determination of FRS2 gene copy number in bladder cancer.
    BMC Cancer. 2025;25:1211.
    PubMed     Abstract available
    
    
    
45. WANG B, Gong Z, Su P, Zhen G, et al
    Multi-machine learning model based on radiomics features to predict prognosis of muscle-invasive bladder cancer.
    BMC Cancer. 2025;25:1116.
    PubMed     Abstract available
    
    
    
46. HUANG L, Yan D, Ruan H, Lin Q, et al
    BAIAP2 as a driver of tumor progression in urothelial bladder cancer.
    BMC Cancer. 2025;25:1057.
    PubMed     Abstract available
    
    
    June 2025
47. PAN Y, Shih HJ, Chuang SH, Chang CP, et al
    Effects of functional antioxidants on the expansion of gamma delta T-cells and their cellular cytotoxicity against bladder cancer cells.
    BMC Cancer. 2025;25:980.
    PubMed     Abstract available
    
    
    May 2025
48. XU M, Zhou J, Lv J, Zhang Y, et al
    Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer analysis.
    BMC Cancer. 2025;25:932.
    PubMed     Abstract available
    
    
    
49. N S, Ps H, P R, Paul L, et al
    Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer.
    BMC Cancer. 2025;25:916.
    PubMed     Abstract available
    
    
    
50. LAN T, Zhu Y, Zhong W, Tan Q, et al
    Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial.
    BMC Cancer. 2025;25:868.
    PubMed     Abstract available
    
    
    April 2025
51. WANG X, Qu Y, Sun Y, Yang T, et al
    ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling.
    BMC Cancer. 2025;25:789.
    PubMed     Abstract available
    
    
    
52. KITAHAMA K, Shigematsu Y, Sugawara E, Amori M, et al
    Clinicopathological characteristics of transcription factor-defined subtypes in bladder small cell carcinoma.
    BMC Cancer. 2025;25:766.
    PubMed     Abstract available
    
    
    
53. QIU H, Deng X, Zha J, Wu L, et al
    Machine learning-based characterization of stemness features and construction of a stemness subtype classifier for bladder cancer.
    BMC Cancer. 2025;25:717.
    PubMed     Abstract available
    
    
    
54. LI Z, Su M, Li Q, Zheng X, et al
    The role of CDK8 gene polymorphisms in bladder cancer susceptibility and prognosis: a study in the Chinese Han population.
    BMC Cancer. 2025;25:714.
    PubMed     Abstract available
    
    
    
55. PLAGE H, Ahlburg V, Hofbauer S, Furlano K, et al
    Loss of chromosome Y is unrelated to the composition of the tumor microenvironment and patient prognosis in muscle-invasive urothelial bladder cancers.
    BMC Cancer. 2025;25:677.
    PubMed     Abstract available
    
    
    March 2025
56. YANG H, Zhang T, Li Z, Cai Y, et al
    Risk factors for in-hospital venous thromboembolism in patients with bladder cancer: A retrospective single-center study.
    BMC Cancer. 2025;25:536.
    PubMed     Abstract available
    
    
    
57. WAN S, Li KP, Chen SY, Wang CY, et al
    Single-cell sequencing combined with urinary multi-omics analysis reveals that the non-invasive biomarker PRDX5 regulates bladder cancer progression through ferroptosis signaling.
    BMC Cancer. 2025;25:533.
    PubMed     Abstract available
    
    
    
58. DAI L, Ye K, Yao G, Lin J, et al
    Using machine learning for predicting cancer-specific mortality in bladder cancer patients undergoing radical cystectomy: a SEER-based study.
    BMC Cancer. 2025;25:523.
    PubMed     Abstract available
    
    
    
59. SHENG Z, Xu J, Wang M, Xu X, et al
    The role of urinary microbiota in primary and recurrent bladder cancer: insights from a propensity score matching study.
    BMC Cancer. 2025;25:468.
    PubMed     Abstract available
    
    
    February 2025
60. CAI J, Yan Z, Zhong Y, Li Y, et al
    Small non-coding RNA profiling in patients with non-muscle invasive bladder cancer.
    BMC Cancer. 2025;25:319.
    PubMed     Abstract available
    
    
    
61. ZHENG Z, Dai F, Liu J, Zhang Y, et al
    Pathology-based deep learning features for predicting basal and luminal subtypes in bladder cancer.
    BMC Cancer. 2025;25:310.
    PubMed     Abstract available
    
    
    
62. YAN L, Liang H, Qi T, Deng D, et al
    Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
    BMC Cancer. 2025;25:297.
    PubMed     Abstract available
    
    
    
63. WANG C, Li K, Huang R, Wan S, et al
    Urine proteomics-based analysis identifies CHI3L1 as an immune marker and potential therapeutic target for bladder cancer.
    BMC Cancer. 2025;25:271.
    PubMed     Abstract available
    
    
    
64. LI Z, Wang Z, Wu J, Zhang F, et al
    Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients.
    BMC Cancer. 2025;25:268.
    PubMed     Abstract available
    
    
    
65. LI KP, Wan S, Wang CY, Chen SY, et al
    Multi-omics analysis reveals the impact of YAP/TEAD4-mediated EIF5A1 expression on mitochondrial apoptosis and bladder cancer progression.
    BMC Cancer. 2025;25:234.
    PubMed     Abstract available
    
    
    
66. LI P, Jing S, Kang Y, Feng B, et al
    Clinical outcomes of nephroureterectomy with bladder cuff excision or radical cystectomy for distal ureteral carcinoma invaded muscle of the ureteral orifice.
    BMC Cancer. 2025;25:221.
    PubMed     Abstract available
    
    
    
67. FURUKAWA J, Kakei Y, Murakami S, Kita H, et al
    Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial.
    BMC Cancer. 2025;25:195.
    PubMed     Abstract available
    
    
    January 2025
68. CHEN T, Zou X, Li Y, Peng L, et al
    Evaluation of the association between lymph node ratio and long-term survival in patients after surgery for lymph node-positive bladder cancer: a SEER population-based study with external validation.
    BMC Cancer. 2025;25:135.
    PubMed     Abstract available
    
    
    November 2024
69. SCHUCK S, Loussikian P, Mebarki A, Malaab J, et al
    Perceived unmet needs and impact on quality of life of patients living with advanced bladder cancer and their caregivers: results of a social media listening study conducted in five European countries.
    BMC Cancer. 2024;24:1444.
    PubMed     Abstract available
    
    
    October 2024
70. FUKUMOTO W, Okamura S, Tamai M, Arima J, et al
    Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.
    BMC Cancer. 2024;24:1333.
    PubMed     Abstract available
    
    
    
71. KARLSSON P, Nygren-Bonnier M, Torikka S, Porserud A, et al
    Patients experiences of an exercise intervention in primary care following robot-assisted radical cystectomy due to bladder cancer: a qualitative study.
    BMC Cancer. 2024;24:1306.
    PubMed     Abstract available
    
    
    
72. SONG J, Sun X, Wang T, Li C, et al
    Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study.
    BMC Cancer. 2024;24:1261.
    PubMed     Abstract available
    
    
    
73. YAO Z, Li Y, Ding Y, Hou Y, et al
    Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters >/=3cm compared to transurethral resection: a non-randomized controlled study.
    BMC Cancer. 2024;24:1239.
    PubMed     Abstract available
    
    
    September 2024
74. PALACKA P, Holickova A, Roska J, Makovicky P, et al
    Prognostic value of nucleotide excision repair and translesion DNA synthesis proteins in muscle-infiltrating bladder carcinoma.
    BMC Cancer. 2024;24:1103.
    PubMed     Abstract available
    
    
    August 2024
75. FAN Z, Liu Y, Wang X, Xu Y, et al
    APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis.
    BMC Cancer. 2024;24:1046.
    PubMed     Abstract available
    
    
    
76. CHEN D, Cao H, Zheng X, Wang H, et al
    Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target.
    BMC Cancer. 2024;24:1024.
    PubMed     Abstract available
    
    
    
77. BOTROUS S, Elmaghraby A, Achy SE, Mustafa Y, et al
    Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A.
    BMC Cancer. 2024;24:971.
    PubMed     Abstract available
    
    
    
78. HAO S, Yang Z, Wang G, Cai G, et al
    Development of prognostic model incorporating a ferroptosis/cuproptosis-related signature and mutational landscape analysis in muscle-invasive bladder cancer.
    BMC Cancer. 2024;24:958.
    PubMed     Abstract available
    
    
    
79. LIU R, Yang T, Huang J, Xiao Z, et al
    Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
    BMC Cancer. 2024;24:947.
    PubMed     Abstract available
    
    
    July 2024
80. CICIN I, Plimack ER, Gurney H, Leibowitz R, et al
    Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.
    BMC Cancer. 2024;23.
    PubMed     Abstract available
    
    
    
81. PORSERUD A, Karlsson P, Aly M, Rydwik E, et al
    Effects of an exercise intervention in primary care after robot-assisted radical cystectomy for urinary bladder cancer: a randomised controlled trial.
    BMC Cancer. 2024;24:891.
    PubMed     Abstract available
    
    
    
82. IQBAL MS, Sardar N, Peng K, Almutairi LA, et al
    Association between CYP1A2 gene variants -163 C/A (rs762551) and -3860 G/A (rs2069514) and bladder cancer susceptibility.
    BMC Cancer. 2024;24:880.
    PubMed     Abstract available
    
    
    
83. MOHAMED AH, Mohamed KA, Kayacan E, Nur Y, et al
    Clinical characteristics and factors associated with survival rate of patients with non-muscle invasive bladder cancer attending at a Tertiary Hospital in Somalia.
    BMC Cancer. 2024;24:839.
    PubMed     Abstract available
    
    
    June 2024
84. ZHANG X, Hong B, Li H, Zhao J, et al
    Basement membrane-related MMP14 predicts poor prognosis and response to immunotherapy in bladder cancer.
    BMC Cancer. 2024;24:746.
    PubMed     Abstract available
    
    
    
85. MENG H, Yang R, Lin Q, Du W, et al
    Isorhapontigenin inhibition of basal muscle-invasive bladder cancer attributed to its downregulation of SNHG1 and DNMT3b.
    BMC Cancer. 2024;24:737.
    PubMed     Abstract available
    
    
    
86. JI J, Zhang T, Zhu L, Yao Y, et al
    Using machine learning to develop preoperative model for lymph node metastasis in patients with bladder urothelial carcinoma.
    BMC Cancer. 2024;24:725.
    PubMed     Abstract available
    
    
    March 2024
87. LI X, Liang Z, Pan J, Zhang M, et al
    Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer.
    BMC Cancer. 2024;24:328.
    PubMed     Abstract available
    
    
    February 2024
88. HUANG LH, Chen CS, Li JR, Chiu KY, et al
    The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy.
    BMC Cancer. 2024;24:247.
    PubMed     Abstract available
    
    
    
89. ZHANG J, Yang M, Wei D, Zhang D, et al
    The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
    BMC Cancer. 2024;24:202.
    PubMed     Abstract available
    
    
    
90. YANG M, Zhang J, Wei D, Yu T, et al
    Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
    BMC Cancer. 2024;24:196.
    PubMed     Abstract available
    
    
    January 2024
91. PAN DL, Zhang LF, Li XJ, Zhang KP, et al
    Feasibility and safety of laparoscopic radical cystectomy for male octogenarians with muscle-invasive bladder cancer.
    BMC Cancer. 2024;24:159.
    PubMed     Abstract available
    
    
    
92. VERGHOTE F, Van Praet C, Berquin C, Lumen N, et al
    Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice.
    BMC Cancer. 2024;24:160.
    PubMed     Abstract available
    
    
    
93. JING S, Yang E, Luo Z, Zhang Y, et al
    Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer.
    BMC Cancer. 2024;24:127.
    PubMed     Abstract available
    
    
    November 2023
94. GORE JL, Wolff EM, Comstock BA, Follmer KM, et al
    Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
    BMC Cancer. 2023;23:1127.
    PubMed     Abstract available
    
    
    
95. ROUSSOT N, Fumet JD, Limagne E, Thibaudin M, et al
    A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
    BMC Cancer. 2023;23:1080.
    PubMed     Abstract available
    
    
    
96. LU L, Chen C, Cheng H, Ding H, et al
    Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1066.
    PubMed     Abstract available
    
    
    October 2023
97. CHEN JX, Huang WT, Zhang QY, Deng CE, et al
    The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:1018.
    PubMed     Abstract available
    
    
    
98. LI Y, Xu K, Zhang Y, Mao H, et al
    Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    BMC Cancer. 2023;23:1021.
    PubMed     Abstract available
    
    
    
99. LUO L, Xie Q, Wu Y, Li P, et al
    Circular RNA CCT3 is a unique molecular marker in bladder cancer.
    BMC Cancer. 2023;23:977.
    PubMed     Abstract available
    
    
    
100. HE Q, Wu S, Zhou Y, Liu Y, et al
     Genetic factors, adherence to healthy lifestyle behaviors, and risk of bladder cancer.
     BMC Cancer. 2023;23:965.
     PubMed     Abstract available
     
     
     
101. ZHENHAI Z, Qi C, Shuchao Z, Zhongqi W, et al
     MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation.
     BMC Cancer. 2023;23:956.
     PubMed     Abstract available
     
     
     
102. TANABE K, Nakanishi Y, Okubo N, Matsumoto S, et al
     Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria II.
     BMC Cancer. 2023;23:940.
     PubMed     Abstract available
     
     
     
103. WANG Y, Pan J, An F, Chen K, et al
     GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
     BMC Cancer. 2023;23:925.
     PubMed     Abstract available
     
     
     September 2023
104. ALT M, Stecca C, Lin Y, Kazeem G, et al
     Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
     BMC Cancer. 2023;23:919.
     PubMed     Abstract available
     
     
     
105. TSAI TH, Su PJ, Huang SY, Kuo MC, et al
     The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.
     BMC Cancer. 2023;23:871.
     PubMed     Abstract available
     
     
     
106. NASR S, Haddad FG, Khazen J, Kattan J, et al
     PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience.
     BMC Cancer. 2023;23:817.
     PubMed     Abstract available
     
     
     August 2023
107. CAI Y, Cheng Y, Wang Z, Li L, et al
     A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
     BMC Cancer. 2023;23:725.
     PubMed     Abstract available
     
     
     
108. JIANG Y, Zhu C, Huang H, Huang G, et al
     TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
     BMC Cancer. 2023;23:716.
     PubMed     Abstract available
     
     
     July 2023
109. LI W, Liu Z, Jin K, Shao F, et al
     Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
     BMC Cancer. 2023;23:661.
     PubMed     Abstract available
     
     
     June 2023
110. KERZELI IK, Kostakis A, Turker P, Malmstrom PU, et al
     Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.
     BMC Cancer. 2023;23:605.
     PubMed     Abstract available
     
     
     
111. LIANG PI, Lai HY, Chan TC, Li WM, et al
     Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
     BMC Cancer. 2023;23:599.
     PubMed     Abstract available
     
     
     
112. LIU J, Wu P, Lai S, Wang J, et al
     Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning.
     BMC Cancer. 2023;23:574.
     PubMed     Abstract available
     
     
     
113. NISHIYAMA H, Tanaka Y, Hamada M, Ozaki M, et al
     Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
     BMC Cancer. 2023;23:565.
     PubMed     Abstract available
     
     
     
114. RUTTEN VC, Salhi Y, Robbrecht GJ, de Wit R, et al
     The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial.
     BMC Cancer. 2023;23:539.
     PubMed     Abstract available
     
     
     
115. KOLL FJ, Doring C, Olah C, Szarvas T, et al
     Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
     BMC Cancer. 2023;23:504.
     PubMed     Abstract available
     
     
     April 2023
116. HUI P, Ni F, Zheng L, Jia L, et al
     Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer.
     BMC Cancer. 2023;23:355.
     PubMed     Abstract available
     
     
     
117. TANG Y, Lei Y, Gao P, Jia J, et al
     Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker.
     BMC Cancer. 2023;23:328.
     PubMed     Abstract available
     
     
     
118. YANG X, Zhang S, Cui Y, Li Y, et al
     Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial.
     BMC Cancer. 2023;23:320.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum